Oni is a biotechnology company in San Diego, CA and Oxford, UK that democratizes the ability to see single molecules within living cells using its desktop Nanoimager microscopy technology. It closed a $75m Series B financing.
ARCH Venture Partners and Casdin Capital led the round, with participation by Section 32, ARTIS Ventures. Vertical Venture Partners, Axon Ventures, Axon Ventures, and private investors.
The company plans to use the funds for R&D and commercial growth in the US and Asia.
- These geographies are driving technology adoption
- Expanding its range of consumables as well as cloud-based software applications.
Oni was founded in 2016 as an Oxford University spin-out and is currently the CEO. The Nanoimager is a desktop, superresolution, single-molecule imaging platform that allows for visualizing and tracking individual molecules within complex systems like nanoparticles and living cells. These applications can be found in the area of extracellular Vesicles, cell therapy, and especially chimeric Antigen T-cell therapy (CAR-T).
The team includes Bo Jing (founder & CEO), and:
Tyler Ralston Ph.D. Chief Technology Officer, previously at Butterfly Network, Tesseract Health
* Christine Nishiyama Vice President Operations, Berkeley Lights
* Don O’Neil MBA, Vice President Commercial Operations – previously with Gemini Bio
* Ricardo Bastos Ph.D. Director of Business Development, who began his career at ONI
* Sophia Mowla, Chief Development Officer – formerly at True Search
Keith Crandell, co-founder and managing director at ARCH Venture Partners, Shaun Rodriguez, Director for Life Science Research at Casdin Capital have joined ONI’s board of directors. Patrick Finn, chief commercial officer at Twist Bioscience, joined the ONI board in 2021.